Cefpodoxime is an extended spectrum semi-synthetic antibiotic which belongs to the third generation of cephalosporins. It inhibits bacterial cell wall synthesis leading to bacterial cell death. Cefpodoxime is given as Cefpodoxime proxetil (prodrug) which is hydrolyzed in the intestinal epithelium to release active drug Cefpodoxime. It is active against broad spectrum of Gram +ve & Gram -ve bacteria. Organisms resistant to penicillins and some cephalosporins due to their b-lactamases secretion are susceptible to Cefpodoxime. It is effective for longer duration with higher clinical success rate and low incidence of side effects.
Lower respiratory tract infections
Upper respiratory tract infections
Urinary tract infections including gonorrhea, cystitis
Skin and soft tissue infections
Acute otitis media
Each Dispersible tablet contains:
Adults : 200mg BID or 400mg OD for 7 -10 days.
In case of URTI & Uncomplicated UTI, dose can be reduced to 100mg BID or 200mg OD. Only single dose of 200mg is recommended in case of Uncomplicated Gonorrhea.
Children : 10 mg/kg/ days or 5 mg/kg every 12 hrs for 10 day (max 400 mg/ day).
Not enough studies to document use in pregnancy.
Cefpodoxime is secreted in human milk. Use with caution.
Safety and effectiveness not established in infants.
(less than two months old)
Diarrhea, Nausea, Vomiting, Abdominal pain, vaginal fungal infections & pruritus.
Known hypersensitivity to cefpodoxime proxetil.
Kefodime 50 is available as a strip of 10 tablets.